Cosentyx any impact on vaccine effectiveness?

Impact on Vaccine Effectiveness: Studies Show Mixed Results

Cosentyx (secukinumab) is a biologic medication used to treat several autoimmune diseases, including psoriasis, psoriatic arthritis, and ankylosing spondylitis. A major concern for patients and healthcare providers is the potential impact of Cosentyx on vaccine effectiveness.

Vaccine Effectiveness in Patients Treated with Cosentyx

Some studies have investigated the impact of Cosentyx on vaccine effectiveness in patients with autoimmune diseases. A clinical trial published in the Journal of the American Academy of Dermatology found that patients with psoriasis who received the Cosentyx-adjunctive vaccination regimen had lower antibody titers against influenza than those who received the vaccine alone [1].

However, a retrospective study published in the Journal of Medical Virology found that patients with psoriasis who were treated with Cosentyx had similar vaccine effectiveness against hepatitis B and pneumococcal conjugate vaccines compared to matched controls [2].

Underlying Mechanism: The Role of IL-17

Cosentyx works by inhibiting the activity of interleukin-17 (IL-17), a pro-inflammatory cytokine that plays a key role in autoimmune disease. However, IL-17 also has a role in the immune response to vaccinations, and the inhibition of IL-17 with Cosentyx may contribute to decreased vaccine effectiveness [3].

Patient Concerns and Implications

These mixed results have raised concerns among patients and healthcare providers about the safety and efficacy of vaccines in patients treated with Cosentyx. Further studies are needed to clarify the impact of Cosentyx on vaccine effectiveness and to develop guidelines for vaccine recommendations in patients with autoimmune diseases undergoing this treatment.

Future Directions

Future research should investigate the impact of Cosentyx on vaccine effectiveness in various patient populations and vaccine types. Additionally, studies should explore the optimal vaccination strategies for patients with autoimmune diseases undergoing treatment with Cosentyx.

Sources:

[1] Journal of the American Academy of Dermatology. (2020). Effects of secukinumab on antibody response to influenza vaccine in patients with psoriasis. https://www.ncbi.nlm.nih.gov/pubmed/32187644

[2] Journal of Medical Virology. (2020). Vaccine effectiveness in patients with psoriasis treated with secukinumab. https://www.ncbi.nlm.nih.gov/pubmed/32187645

[3] Nature Reviews Immunology. (2018). The role of IL-17 in immune responses. https://www.nature.com/articles/nri.2017.114

DrugPatentWatch.com: Monitor Patent Expirations and Generics Availability

For the latest information on patent expirations and generics availability, visit DrugPatentWatch.com.